Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.
暂无分享,去创建一个
Y. Sugiyama | Kiyomi Ito | T Iwatsubo | Y Sugiyama | T. Iwatsubo | K Ito | Y. Nakajima | K. Ito | S Kanamitsu | Y Nakajima | S. Kanamitsu
[1] H Suzuki,et al. [Kinetic analysis of hepatobiliary transport of drugs: importance of carrier-mediated transport]. , 1995, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[2] R. Kato,et al. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. , 1994, Pharmacogenetics.
[3] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[4] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[5] D. Warnock,et al. Pharmacokinetics of ketoconazole in normal subjects. , 1981, The Journal of antimicrobial chemotherapy.
[6] T Iwatsubo,et al. PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.
[7] T. Andersson,et al. Omeprazole: pharmacokinetics and metabolism in man. , 1989, Scandinavian journal of gastroenterology. Supplement.
[8] J S Harmatz,et al. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.
[9] Y. Sugiyama,et al. Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. , 1998, The Journal of pharmacology and experimental therapeutics.
[10] Kaoru Kobayashi,et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.
[11] R. Gugler,et al. Omeprazole inhibits oxidative drug metabolism , 1985 .
[12] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[13] M. Kendall,et al. The effect of age on the pharmacokinetics of metoprolol and its metabolites. , 1981, British journal of clinical pharmacology.
[14] M. Grant,et al. Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. , 1987, Biochemical pharmacology.
[15] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[16] J. Houston,et al. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[17] J. Kolars,et al. First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.
[18] M. Rowland,et al. Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model , 1986, The Journal of pharmacy and pharmacology.
[19] M. Yamazaki,et al. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. , 1994, The Journal of pharmacology and experimental therapeutics.
[20] P. Beaune,et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.
[21] R. Kato,et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.
[22] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[23] J. Houston,et al. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. , 1995, The Journal of pharmacology and experimental therapeutics.
[24] Tucker Gt,et al. The rational selection of drug interaction studies: implications of recent advances in drug metabolism. , 1992 .
[25] M. Rowland,et al. Models of hepatic drug clearance: discrimination between the ‘well stirred’ and ‘parallel‐tube’ models , 1983, The Journal of pharmacy and pharmacology.
[26] M. Chiba,et al. Metabolism: Scaling-up from In Vitro to Organ and Whole Body , 1994 .
[27] D. Back,et al. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. , 1988, British journal of clinical pharmacology.
[28] Y. Sugiyama,et al. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.
[29] J. Miners,et al. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers , 1990, Clinical pharmacology and therapeutics.
[30] R. Thomas,et al. The metabolic fate of tolbutamide in man and in the rat. , 1966, Journal of medicinal chemistry.
[31] E. Johnson,et al. Influence of food on the pharmacokinetics of ketoconazole , 1984, Antimicrobial Agents and Chemotherapy.
[32] R. Gugler,et al. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. , 1985, Gastroenterology.
[33] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[34] B. Hoener,et al. Predicting the hepatic clearance of xenobiotics in humans from in vitro data , 1994, Biopharmaceutics & drug disposition.
[35] C. L. Ferguson,et al. Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.
[36] D. Greenblatt,et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. , 1994, British journal of clinical pharmacology.
[37] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[38] Y. Sugiyama,et al. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. , 1997, The Journal of pharmacology and experimental therapeutics.
[39] D. Jones,et al. Models of hepatic elimination , 1986, Hepatology.
[40] J. Miners,et al. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. , 1988, Biochemical pharmacology.
[41] C. Libersa,et al. Mexiletine metabolism in vitro by human liver. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[42] C. Crespi. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .
[43] G R Wilkinson,et al. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.
[44] J. Houston,et al. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. , 1987, Drug metabolism and disposition: the biological fate of chemicals.
[45] J. Kolars,et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.
[46] T. Izumi,et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. , 1996, The Journal of pharmacology and experimental therapeutics.
[47] D. Greenblatt,et al. Metabolism of Drugs by Cytochrome P450 3A Isoforms , 1995, Clinical pharmacokinetics.
[48] Y. Sugiyama,et al. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. , 1993, The American journal of physiology.
[49] E. Nelson,et al. Kinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide administration. , 1961, The Journal of pharmacology and experimental therapeutics.
[50] Y. Sai,et al. Active Secretion of Drugs from the Small Intestinal Epithelium in Rats by P‐Glycoprotein Functioning as an Absorption Barrier , 1996, The Journal of pharmacy and pharmacology.
[51] R. Hook,et al. Pharmacokinetics and biotransformation studies of terfenadine in man. , 1982, Arzneimittel-Forschung.
[52] P. Beaune,et al. Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. , 1990, European journal of biochemistry.
[53] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[54] Y. Sugiyama,et al. Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. , 1995, Toxicology letters.
[55] E. Mini,et al. Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.
[56] D. Greenblatt,et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. , 1996, Journal of clinical psychopharmacology.
[57] T. Kamataki,et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.
[58] D. Greenblatt,et al. In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic Interaction , 1994, Journal of clinical pharmacology.
[59] M. Kristensen,et al. SULPHAPHENAZOLE-INDUCED HYPOGLYCAEMIC ATTACKS IN TOLBUTAMIDE-TREATED DIABETICS. , 1963, Lancet.
[60] T. Izumi,et al. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. , 1997, The Journal of pharmacology and experimental therapeutics.
[61] M. Lieh-Lai,et al. Drug-Induced Torsades De Pointes: A Possible Interaction of Terfenadine and Erythromycin , 1994, The Annals of pharmacotherapy.
[62] J. Lin,et al. Kinetic studies on the deethylation of ethoxybenzamide. A comparative study with isolated hepatocytes and liver microsomes of rat. , 1980, Biochemical pharmacology.
[63] R. Elofsson,et al. Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. , 1974, Acta pharmaceutica Suecica.
[64] K. Bischoff,et al. Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.
[65] L. Bass,et al. Physiologically based models and strategic experiments in hepatic pharmacology. , 1988, Biochemical pharmacology.
[66] G. de Sousa,et al. Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. , 1991, Biochemical pharmacology.
[67] G L Amidon,et al. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. , 1990, Gastroenterology.
[68] F. Guengerich,et al. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. , 1991, Gastroenterology.
[69] A. Rane,et al. Morphine glucuronidation in the rhesus monkey: a comparative in vivo and in vitro study. , 1984, The Journal of pharmacology and experimental therapeutics.
[70] G R Wilkinson,et al. Clearance approaches in pharmacology. , 1987, Pharmacological reviews.
[71] J. Lin,et al. Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[72] J. Miners,et al. Characterisation of theophylline metabolism in human liver microsomes. , 1987, British journal of clinical pharmacology.
[73] J S Harmatz,et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.
[74] T. Leemann,et al. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.
[75] K H Antonin,et al. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. , 1976, The Journal of pharmacology and experimental therapeutics.
[76] R. Chenery,et al. Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. , 1989, Biochemical pharmacology.
[77] W. L. Nelson,et al. Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[78] D. Greenblatt,et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. , 1995, Journal of clinical psychopharmacology.
[79] P. Beaune,et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.
[80] M. Bayliss,et al. Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. , 1990, Biochemical Society transactions.
[81] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[82] P. Robinson,et al. Hepatic elimination of flowing substrates: the distributed model. , 1978, Journal of theoretical biology.
[83] Y. Sugiyama,et al. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration. , 1996, The Journal of toxicological sciences.